This company listing is no longer active
23I Stock Overview
A biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in psychiatric and neurological disorders in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 6/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Intra-Cellular Therapies, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$122.00 |
| 52 Week High | US$127.00 |
| 52 Week Low | US$60.00 |
| Beta | 0.70 |
| 1 Month Change | -0.81% |
| 3 Month Change | 52.50% |
| 1 Year Change | 100.00% |
| 3 Year Change | 109.48% |
| 5 Year Change | 759.15% |
| Change since IPO | 901.15% |
Recent News & Updates
Recent updates
Shareholder Returns
| 23I | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | 0.8% | -6.6% | 0.8% |
| 1Y | 100.0% | -27.7% | 14.6% |
Return vs Industry: 23I exceeded the German Pharmaceuticals industry which returned -21.9% over the past year.
Return vs Market: 23I exceeded the German Market which returned 7.6% over the past year.
Price Volatility
| 23I volatility | |
|---|---|
| 23I Average Weekly Movement | 10.7% |
| Pharmaceuticals Industry Average Movement | 5.7% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in DE Market | 12.7% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: 23I's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 23I's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 860 | Sharon Mates | www.intracellulartherapies.com |
Intra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in psychiatric and neurological disorders in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing lumateperone, which is in Phase 3 clinical trial for the treatment of major depressive disorder, as well as schizophrenia in pediatric patients, bipolar disorder, and irritability associated with autism spectrum disorder.
Intra-Cellular Therapies, Inc. Fundamentals Summary
| 23I fundamental statistics | |
|---|---|
| Market cap | €13.00b |
| Earnings (TTM) | -€69.22m |
| Revenue (TTM) | €631.08m |
20.6x
P/S Ratio-187.8x
P/E RatioIs 23I overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 23I income statement (TTM) | |
|---|---|
| Revenue | US$680.85m |
| Cost of Revenue | US$293.08m |
| Gross Profit | US$387.77m |
| Other Expenses | US$462.44m |
| Earnings | -US$74.68m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.70 |
| Gross Margin | 56.95% |
| Net Profit Margin | -10.97% |
| Debt/Equity Ratio | 0% |
How did 23I perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/01 23:52 |
| End of Day Share Price | 2025/04/01 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Intra-Cellular Therapies, Inc. is covered by 8 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Robert Hazlett | BTIG |
| Jason Butler | Citizens JMP Securities, LLC |
| Corinne Johnson | Goldman Sachs |